Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice
- The US Food and Drug Administration has determined that semaglutide is no longer in shortage, impacting patients who use compounded versions of the medication.
- The US Food and Drug Administration has removed semaglutide from its shortage list, allowing Novo Nordisk's Ozempic and Wegovy to be widely available for patients.
- Novo Nordisk can now meet the current and future demand in the US for its diabetes and weight-loss medications, ending a two-year shortage.
Insights by Ground AI
Does this summary seem wrong?
47 Articles
47 Articles
All
Left
8
Center
18
Right
5
Coverage Details
Total News Sources47
Leaning Left8Leaning Right5Center18Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 26%
C 58%
R 16%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage